KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Working Capital Changes (2017 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Other Working Capital Changes for 16 consecutive years, with -$19.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes rose 24.17% year-over-year to -$19.2 million, compared with a TTM value of -$50.6 million through Dec 2025, down 1468.13%, and an annual FY2025 reading of -$50.6 million, down 1468.13% over the prior year.
  • Other Working Capital Changes was -$19.2 million for Q4 2025 at Alnylam Pharmaceuticals, down from $8.9 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $75.5 million in Q1 2024 and bottomed at -$86.5 million in Q4 2022.
  • Average Other Working Capital Changes over 5 years is -$8.1 million, with a median of -$12.7 million recorded in 2022.
  • The sharpest move saw Other Working Capital Changes plummeted 4312.73% in 2021, then soared 22295.57% in 2023.
  • Year by year, Other Working Capital Changes stood at $19.7 million in 2021, then plummeted by 538.24% to -$86.5 million in 2022, then soared by 79.81% to -$17.5 million in 2023, then tumbled by 44.74% to -$25.3 million in 2024, then rose by 24.17% to -$19.2 million in 2025.
  • Business Quant data shows Other Working Capital Changes for ALNY at -$19.2 million in Q4 2025, $8.9 million in Q3 2025, and -$13.1 million in Q2 2025.